Abstract
INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of COVID-19, can progress to life-threatening disease and multiorgan failure, and the degree of circulating SARS-CoV-2 directly correlates to clinical deterioration and mortality. The engineered FcMBL protein binds numerous pathogens, including SARS-CoV-2, and pathogenic debris known as pathogen-associated molecular patterns (PAMPs). CASE PRESENTATION: We report the first clinical use of an extracorporeal filter utilizing FcMBL to bind and remove pathogens and PAMPs from the circulation of a critically ill patient with COVID-19-induced multiorgan failure. CONCLUSION: This case highlights the feasibility of using the novel filter to reduce the circulating pathogen load in patients with severe infection through the use of agnostic pathogen binding via FcMBL.